Hematologic Oncology

Gilead has announced plans to acquire Kite Pharma for $180.00 per share in cash, totaling approximately $11.9 billion.

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses additional subsets of acute myeloid leukemia (AML) that CPX-351 (Vyxeos) demonstrates efficacy in.

Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses evolving paradigms in treatment of patients with acute myeloid leukemia (AML).

Results from the phase III ENDEAVOR trial showed that carfilzomib (Kyprolis) reduced the risk of death by 21% compared with bortezomib (Velcade) in patients with relapsed/refractory multiple myeloma

David J. Andorsky, MD, medical oncology/hematology, Rocky Mountain Cancer Centers, discusses the next steps of the phase IIIb randomized MAGNIFY study of lenalidomide (Revlimid) plus rituximab (Rituxan) followed by maintenance therapy in relapsed/refractory non-Hodgkin lymphoma, focusing on a cohort of patients with follicular lymphoma.

Hospice enrollment is low and use of aggressive treatment is high for elderly patients with acute myeloid leukemia, a situation investigators called “suboptimal” in results from a retrospective study.

Judith Trotman, MD, clinical associate professor, medicine, Concord Clinical School, The University of Sydney, discusses results of a trial investigating BGB-3111 in patients with Waldenstrom’s macroglobulinemia.

Jessica K. Altman, MD, associate professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern Medicine, discusses an early-phase study of gilteritinib in FLT3-mutation–positive patients with acute myeloid leukemia (AML).

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses unique characteristics of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).

Arsenic trioxide consolidation was effective and safe in newly diagnosed pediatric patients with acute promyelocytic leukemia, allowing a significant reduction in cumulative anthracycline doses

Eunice Wang, MD, discusses the next steps for crenolanib and other emerging FLT3 inhibitors in AML.

Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses advancements emerging on the horizon in acute myeloid leukemia (AML).

In a small study of pediatric patients with relapsed/refractory ALK-positive anaplastic large cell lymphoma, treatment with 165 mg/m2 of crizotinib (Xalkori) was associated with an overall response rate of 83%

Gilteritinib, a selective TKI against FLT3, demonstrated a favorable safety profile and consistent FLT3 inhibition in adults with relapsed/refractory acute myeloid leukemia.